Clinical Trial

A Phase 1b/2 Study of CAR T Cell Therapy Targeting CD19 and BCMA in Participants With Relapsed or Refractory AL Amyloidosis.

Study acronym: ALACRITY
Recruiting Phase 1/2
View on ClinicalTrials.gov →
Summary
Open-label Phase 1b/2 study with primary objective of this study is to evaluate the safety, tolerability and efficacy of AZD0120 in participants with light chain (AL) amyloidosis.
Protocol Amendment History 1 change
critical Primary endpoint(s) modified 2026-07-03
Trial Details
NCT Number NCT07081646
Lead Sponsor Alexion Pharmaceuticals, Inc.
Conditions Relapsed AL Amyloidosis, Refractory AL Amyloidosis, Light Chain Amyloidosis, Amyloidosis
Enrollment 91 participants
Start Date 2025-08-18
Primary Completion 2029-08-15 (estimated)
Study Completion 2031-02-14 (estimated)
Updated on ClinicalTrials.gov 2026-07-02